Abstract: A method for identifying relationships between nodes in a graph is provided. The method comprises determining a count of relationships for each relationship type associated with each node in a pair of nodes on the graph. The relationship types are represented by edges connected to the nodes in the pair of nodes. A number of common relationships are determined between the pair of nodes for each relationship type. A count for each common relationship is determined for the number of common relationships between the pair of nodes. A similarity coefficient for each common relationship is determined based on the count for each common relationship and the count of relationships for each relationship type associated with each node in the pair of nodes. A weighted score is generated to represent strength for relationships between the pair of nodes using the similarity coefficients.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: In a network with varying levels of Quality of Service, where a UE connects to an application through a network or network slice whose service characteristics are not well defined to the user or the application provider, poor levels of service may be experienced. This may be attributed to the application being poorly designed, where in fact it is related to the UE and application connecting through a network that is not properly configured for the intended usage. To mitigate these issues, applications and UEs can be provided access, directly or indirectly, to a network configuration environment to allow for a standardized QoS request to be issued to the network entities between the UE and application execution environment.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: A system and method for generating a coordinated set of peripheral devices that possess the ability to connect and disconnect as a coordinated set to each of multiple Information Handling Systems (IHSs). In an illustrative, non-limiting embodiment, an IHS may include computer-executable instructions to receive an advertisement from a first peripheral device from among a plurality of peripheral devices. Each peripheral device is configured with a common secret group identity key that identifies the peripheral devices as belonging to a coordinated group. When the first peripheral device is recognized as a member of the coordinated group according to the advertisement, perform a discovery operation to identify the first peripheral device and the other peripheral devices using the secret group identity key, and connect the IHS with the first peripheral device and the other peripheral devices that belong to the coordinated set.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Systems and methods for video management in a conference room using a video bar are described. In an illustrative, non-limiting embodiment, a video bar may include a processor and a memory coupled to the processor, the memory having program instructions stored thereon that, upon execution by the processor, cause the video bar to determine a location of an Information Handling System (IHS) in a conference room, and, at least in part in response to the location, operate a video device in the conference room.

Abstract: Systems and methods for determining the distance, location, position, and orientation of devices in a conference room using a video bar are described. In an illustrative, non-limiting embodiment, a video bar may include a processor and a memory coupled to the processor, the memory having program instructions stored thereon that, upon execution by the processor, cause the video bar to: transmit a signal in a conference room; in response to the transmission, receive an acknowledgement from a client Information Handling System (IHS) in the conference room, and determine a distance between the video bar and the client IHS based, at least in part, upon a Time-of-Flight (ToF) calculation, where the ToF calculation is based, at least in part, upon a difference between: (i) a time the acknowledgement is received, and (ii) a time of the transmission.

Abstract: Systems and methods for audio management in a conference room using a video bar are described. In an illustrative, non-limiting embodiment, a video bar may include a processor and a memory coupled to the processor, the memory having program instructions stored thereon that, upon execution by the processor, cause the video bar to determine a location of an Information Handling System (IHS) in a conference room and, at least in part in response to the location, operate an audio device in the conference room.

Abstract: Methods, systems, and devices for illness detection are described. A method may include receiving heart rate variability (HRV) data associated with a user from a wearable device, the HRV data collected via the wearable device throughout a first time interval and a second time interval subsequent to the first time interval. The method may include inputting the HRV data into a classifier, and identifying a satisfaction of deviation criteria between a first subset of the HRV data collected throughout the first time interval and a second subset of the HRV data collected throughout the second time interval. The method may include causing a graphical user interface (GUI) of a user device to display an illness risk metric for the user based on the satisfaction of the deviation criteria, the illness risk metric associated with a relative probability that the user will transition from a healthy state to an unhealthy state.

Abstract: Apparatus and method for a scalable pricing engine. A scalable pricing engine is operable in a low-scale mode and a high-scale or scalable mode to process pricing data in response to pricing requests. The pricing engine operates in a first runtime environment in the low-scale mode in which it can service pricing requests up to a threshold number and in which the pricing data can be updated and tested. The pricing engine also operates in a second runtime environment which is a scalable runtime supporting pricing requests above the specified threshold. The scalable runtime and pricing engine rely on a scalable read-only data service which distributes a read-only copy of at least a portion of the pricing data from the primary database, a high-scale cache to reduce access latency, data processing and network resource allocations, and data reduction techniques when processing requests and responses.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Systems and methods for load balancing connections for collaboration networking are described. In an illustrative, non-limiting embodiment, a first Information Handling System (IHS) may include: a processor; and a memory coupled to the processor, where the memory includes program instructions store thereon that, upon execution by the processor, cause the first IHS to: establish at least one peer-to-peer (P2P) connection with at least a second IHS of a P2P network; obtain a request to join the P2P network from a third IHS while the P2P network is configured with a first P2P network topology; and direct the third IHS to join the P2P network, where, at least after the join, the P2P network is configured with a second P2P network topology.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Disclosed in some examples are methods, systems, and machine-readable mediums which customizes application feature settings using ranked clusters from an unsupervised modelling algorithm that clusters similar computing platforms and feature settings templates that map these ranks to feature settings. In some examples, a model may is periodically built using a first set of computing platform properties observed from computing platforms that the application is executing on. These clusters are then ranked using a second set of computing platform properties observed from other computing platforms that the application is executing on and performance data that describes performance of the application on those platforms.

Abstract: Aspects of the subject disclosure may include, for example, obtaining for a first path carrying first network traffic a corresponding first alternate path; obtaining for a second path carrying second network traffic a corresponding second alternate path, at least a first portion of the first alternate path being the same as at least a second portion of the second alternate path; responsive to a first detected failure on the first path, causing communication of first re-directed network traffic via the first alternate path instead of via the first path; responsive to a second detected failure on the second path, detecting whether total traffic, including the first re-directed network traffic, on the first portion of the first alternate path meets a threshold; responsive to the detected meeting of the threshold, obtaining for the second path a corresponding back-up alternate path; and causing communication of second re-directed network traffic via the back-up alternative path instead of via the second path.